NAD+ vs MOTS-c: Substrate vs Signal, Evidence, FDA Status, Dosing and Cost

NAD+ is nicotinamide adenine dinucleotide, a coenzyme made from a form of vitamin B3. It is not a peptide, not a hormone and not a stimulant, and it does not bind a receptor. Every cell makes it, mostly by recycling nicotinamide through nicotinamide mononucleotide (NMN); nicotinamide riboside (NR) is another way in. Most of the human trial literature is about those oral precursors rather than NAD+ itself. The full reference is at what is NAD+ injection.

• Electron carrier. NAD+ takes electrons from broken-down glucose and fat, becomes NADH, and hands them to the mitochondria to make ATP.
• Sirtuins and PARP enzymes. Both enzyme families consume NAD+, sirtuins in cell stress responses and PARPs in DNA repair. A 2015 review in Science argued that falling NAD+ limits sirtuin activity with age, from cell and animal work.
• Decline with age. A 2012 PLOS ONE study measured lower NAD+ in older human skin, an observational finding.

Oral NR and NMN reliably raise blood NAD+ in randomized trials, with small and mixed functional effects: no improvement in insulin sensitivity in a 2018 trial in men, improved muscle insulin sensitivity in a 2021 trial in women with prediabetes, and modestly longer walking distances in a 2023 NMN trial and a 2024 NR trial in artery disease. The one study of NAD+ given directly, a 2019 intravenous pilot, found the molecule cleared as fast as it arrived. There are no randomized trials of subcutaneous NAD+ injection. More is in NAD+ benefits.

MOTS-c is a 16-amino-acid peptide whose gene sits in the mitochondria's own DNA rather than in the cell nucleus, inside the gene for the 12S ribosomal RNA. It was identified in a 2015 paper in Cell Metabolism from a group at the University of Southern California, and it belongs to a small family, with humanin, of mitochondrial-derived peptides. Its name is a location code: "mitochondrial open reading frame of the 12S rRNA-c." It is not a growth hormone secretagogue, not a GLP-1 medication and not a stimulant. The full reference is at what is MOTS-c.

• The folate cycle and AMPK. In cultured cells, MOTS-c was reported to slow the folate cycle, causing a molecule called AICAR to build up, which activates AMPK, the cell's low-fuel sensor and the same enzyme exercise switches on. Skeletal muscle appeared to be the main target.
• Signalling to the nucleus. A 2018 Cell Metabolism paper reported that under glucose restriction MOTS-c moves into the nucleus and changes which genes are switched on.
• Muscle and the exercise link. A 2021 Nature Communications paper reported better physical performance in treated mice of all ages, and that in humans a bout of exercise raised the body's own MOTS-c. That human finding is observational, and it is where the "exercise mimetic" label comes from.
• Fat and bone in mice. Studies in ovariectomized mice reported more brown-fat activity and less bone loss.

All of the mechanism work is in mice and cells.

There are no randomized controlled trials of MOTS-c in humans. Human data is observational: exercise raises it, and one cross-sectional study reported lower levels in people with type 2 diabetes, while two others found similar levels with and without obesity. A genetic study across 27,527 people linked an East Asian variant of MOTS-c to higher type 2 diabetes prevalence in men. The closest thing to a treatment trial was of a modified analogue called CB4211, a different molecule, in a small Phase 1 programme whose results were company announcements and which did not advance. More is in MOTS-c benefits.

NAD+ is the usual starting point when the complaint is energy or fatigue, after ordinary causes like B12, thyroid, iron and sleep have been checked. It has the larger human research base on raising levels in people, it is not prohibited in sport, and it does not depend on a training plan to make sense.

MOTS-c suits someone whose interest is metabolic: training tolerance, fuel handling, body composition, and who has a training and nutrition plan in place. Its mechanism is an exercise-signalling pathway, and prescribers describe it as something taken alongside exercise, not instead of it. It is more often prescribed inside a blend than alone. It is not an option for anyone in a tested sport.

They work through different described mechanisms and some prescribers combine them, but no trial has tested the combination. If you want both, say so on the intake; each would come with its own directions printed on its vial. The schedules do not overlap neatly, NAD+ three times a week and MOTS-c on weekday mornings, so a written routine helps.